From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

Interview With Lauren E. Bigham, PhD: The Psychosocial Needs of Patients Receiving CAR T-Cell Therapy, Part 2

View all
FROM THE EDITOR

Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Sarah Jimenez Liza Rodriguez

Sarah Jimenez, DNP,
AGACNP-BC, AOCNP
 BMT/IEC Advanced Practice Provider
Blood and Marrow Transplantation/Immune Effector Cell Therapy Program
Augusta University/Georgia Cancer Center

Liza Rodriguez, DNP, E-MBA, APRN, AOCNP
 APP Manager Hematology/Blood and Marrow Transplant Program
APP Council Chair
Division of Hematologic Malignancies and Cellular Therapeutics
The University of Kansas Cancer Center

Resources

NCCN: Immunotherapy Side Effects - CAR T-Cell Therapy

CAR T-Cell Therapy for Large B-Cell Lymphoma

The EBMT/EHA CAR-T Cell Handbook

ASTCT NucleusPlus: Insights on Emerging CAR-T Therapies

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

News & Literature Highlights

Trends in Pharmacological Sciences

Boosting CAR-T cell therapy through vaccine synergy

International Immunopharmacology

The paths toward immunotherapy of esophageal cancer: An overview of clinical trials

Critical Reviews in Oncology/Hematology

Chimeric antigen receptor T cell immunotherapy for gynecological malignancies

Oncogene

Preclinical application of a CD155 targeting chimeric antigen receptor T cell therapy for digestive system cancers

Science Advances

Development of an antigen-based approach to noninvasively image CAR T cells in real time and as a predictive tool

Blood

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Blood Advances

Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network

Nature Medicine

Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

Blood Advances

EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients post CD19-CAR T cell therapy

Blood Advances

Access barriers to anti-CD19+ CAR T-cell therapy for NHL across a community transplant and cellular therapy network

Advertisement
Case Studies

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

B-Cell Aplasia, Hypogammaglobulinemia Can Result in Serious, Life-Threatening Infections

Fast Facts

Fast Facts #12: BCMA Targets

Advertisement
Quizzes
Test your knowledge of atypical manifestation of neurotoxicity following CAR T-cell therapy
Test your knowledge of CAR T-cell therapy
Test your knowledge of CAR T-cell infusion in an outpatient setting